Cargando…

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study

AIMS: To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases. METHODS: Patients free from CVRD were identified from healthcare records in England, Germany, Ja...

Descripción completa

Detalles Bibliográficos
Autores principales: Birkeland, Kåre I., Bodegard, Johan, Eriksson, Jan W., Norhammar, Anna, Haller, Hermann, Linssen, Gerard C.M., Banerjee, Amitava, Thuresson, Marcus, Okami, Suguru, Garal‐Pantaler, Elena, Overbeek, Jetty, Mamza, Jil Billy, Zhang, Ruiqi, Yajima, Toshitaka, Komuro, Issei, Kadowaki, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496468/
https://www.ncbi.nlm.nih.gov/pubmed/32363737
http://dx.doi.org/10.1111/dom.14074
_version_ 1783583103748407296
author Birkeland, Kåre I.
Bodegard, Johan
Eriksson, Jan W.
Norhammar, Anna
Haller, Hermann
Linssen, Gerard C.M.
Banerjee, Amitava
Thuresson, Marcus
Okami, Suguru
Garal‐Pantaler, Elena
Overbeek, Jetty
Mamza, Jil Billy
Zhang, Ruiqi
Yajima, Toshitaka
Komuro, Issei
Kadowaki, Takashi
author_facet Birkeland, Kåre I.
Bodegard, Johan
Eriksson, Jan W.
Norhammar, Anna
Haller, Hermann
Linssen, Gerard C.M.
Banerjee, Amitava
Thuresson, Marcus
Okami, Suguru
Garal‐Pantaler, Elena
Overbeek, Jetty
Mamza, Jil Billy
Zhang, Ruiqi
Yajima, Toshitaka
Komuro, Issei
Kadowaki, Takashi
author_sort Birkeland, Kåre I.
collection PubMed
description AIMS: To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases. METHODS: Patients free from CVRD were identified from healthcare records in England, Germany, Japan, the Netherlands, Norway and Sweden at a fixed date. CVRD manifestation was defined by first diagnosis of cardiorenal disease, or a stroke, myocardial infarction (MI) or peripheral artery disease (PAD) event. The mortality risk associated with single CVRD history of heart failure (HF), chronic kidney disease (CKD), MI, stroke or PAD was compared with that associated with CVRD‐free status. RESULTS: Of 1 177 896 patients with T2D, 772 336 (66%) were CVRD‐free and followed for a mean of 4.5 years. A total of 137 081 patients (18%) developed a first CVRD manifestation, represented by CKD (36%), HF (24%), stroke (16%), MI (14%) and PAD (10%). HF or CKD was associated with increased cardiovascular and all‐cause mortality risk: hazard ratio (HR) 2.02 (95% confidence interval [CI] 1.75–2.33) and HR 2.05 (95% CI 1.82–2.32), respectively. HF and CKD were separately associated with significantly increased mortality risks, and the combination was associated with the highest cardiovascular and all‐cause mortality risk: HRs 3.91 (95% CI 3.02–5.07) and 3.14 (95% CI 2.90–3.40), respectively. CONCLUSION: In a large multinational study of >750 000 CVRD‐free patients with T2D, HF and CKD were consistently the most frequent first cardiovascular disease manifestations and were also associated with increased mortality risks. These novel findings show these cardiorenal diseases to be important and serious complications requiring improved preventive strategies.
format Online
Article
Text
id pubmed-7496468
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-74964682020-09-25 Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study Birkeland, Kåre I. Bodegard, Johan Eriksson, Jan W. Norhammar, Anna Haller, Hermann Linssen, Gerard C.M. Banerjee, Amitava Thuresson, Marcus Okami, Suguru Garal‐Pantaler, Elena Overbeek, Jetty Mamza, Jil Billy Zhang, Ruiqi Yajima, Toshitaka Komuro, Issei Kadowaki, Takashi Diabetes Obes Metab Original Articles AIMS: To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases. METHODS: Patients free from CVRD were identified from healthcare records in England, Germany, Japan, the Netherlands, Norway and Sweden at a fixed date. CVRD manifestation was defined by first diagnosis of cardiorenal disease, or a stroke, myocardial infarction (MI) or peripheral artery disease (PAD) event. The mortality risk associated with single CVRD history of heart failure (HF), chronic kidney disease (CKD), MI, stroke or PAD was compared with that associated with CVRD‐free status. RESULTS: Of 1 177 896 patients with T2D, 772 336 (66%) were CVRD‐free and followed for a mean of 4.5 years. A total of 137 081 patients (18%) developed a first CVRD manifestation, represented by CKD (36%), HF (24%), stroke (16%), MI (14%) and PAD (10%). HF or CKD was associated with increased cardiovascular and all‐cause mortality risk: hazard ratio (HR) 2.02 (95% confidence interval [CI] 1.75–2.33) and HR 2.05 (95% CI 1.82–2.32), respectively. HF and CKD were separately associated with significantly increased mortality risks, and the combination was associated with the highest cardiovascular and all‐cause mortality risk: HRs 3.91 (95% CI 3.02–5.07) and 3.14 (95% CI 2.90–3.40), respectively. CONCLUSION: In a large multinational study of >750 000 CVRD‐free patients with T2D, HF and CKD were consistently the most frequent first cardiovascular disease manifestations and were also associated with increased mortality risks. These novel findings show these cardiorenal diseases to be important and serious complications requiring improved preventive strategies. Blackwell Publishing Ltd 2020-06-03 2020-09 /pmc/articles/PMC7496468/ /pubmed/32363737 http://dx.doi.org/10.1111/dom.14074 Text en © 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Birkeland, Kåre I.
Bodegard, Johan
Eriksson, Jan W.
Norhammar, Anna
Haller, Hermann
Linssen, Gerard C.M.
Banerjee, Amitava
Thuresson, Marcus
Okami, Suguru
Garal‐Pantaler, Elena
Overbeek, Jetty
Mamza, Jil Billy
Zhang, Ruiqi
Yajima, Toshitaka
Komuro, Issei
Kadowaki, Takashi
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
title Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
title_full Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
title_fullStr Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
title_full_unstemmed Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
title_short Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
title_sort heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496468/
https://www.ncbi.nlm.nih.gov/pubmed/32363737
http://dx.doi.org/10.1111/dom.14074
work_keys_str_mv AT birkelandkarei heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT bodegardjohan heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT erikssonjanw heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT norhammaranna heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT hallerhermann heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT linssengerardcm heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT banerjeeamitava heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT thuressonmarcus heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT okamisuguru heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT garalpantalerelena heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT overbeekjetty heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT mamzajilbilly heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT zhangruiqi heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT yajimatoshitaka heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT komuroissei heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy
AT kadowakitakashi heartfailureandchronickidneydiseasemanifestationandmortalityriskassociationsintype2diabetesalargemultinationalcohortstudy